Breaking News Instant updates and real-time market news.

TSLA

Tesla

$305.75

-2.03 (-0.66%)

, CAR

Avis Budget

$25.66

-0.45 (-1.72%)

09:18
02/11/19
02/11
09:18
02/11/19
09:18

Fly Intel: Pre-market Movers

HIGHER: Tesla (TSLA), up 2% after Canaccord upgraded the stock to Buy from Hold with analyst Jed Dorsheimer stating that he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. He believes the last two quarters and recent guidance have removed significant concerns for both production capability and profitability of the Model 3... Avis Budget (CAR), up 7% after Goldman Sachs analyst David Tamberrino double upgraded shares to Buy from Sell and raised his price target to $35 from $30. Trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion, Tamberrino tells investors in a research note... NuVasive (NUVA), up 15% after a Financial Times report claiming that Smith & Nephew (SNN) has held talks to acquire the company. UP AFTER EARNINGS: Restaurant Brands (QSR), up 4%. DOWN AFTER EARNINGS: Avaya (AVYA), down 7.5%. LOWER: Nvidia (NVDA), down 2% after Bernstein analyst Stacy Rasgon downgraded shares to Market Perform from Outperform following the company's "somewhat chilly guidance cut," which appears much more fundamentally demand-driven, with the question of the "true" run-rate of the gaming business remaining up in the air for now... CommVault Systems (CVLT), down 4% after Piper Jaffray analyst Andrew Nowinski downgraded the stock to Neutral and lowered his price target for the shares to $66 from $71... Bed Bath & Beyond (BBBY), down 2% after Loop Capital analyst Anthony Chukumba downgraded the stock to Sell and lowered his price target for the shares to $12 from $13. The recent rally in the shares is unwarranted as management's "much better-than-expected" fiscal 2019 financial guidance is "unrealistic," Chukumba tells investors... Smith & Nephew, down 5% after the Financial Times' report about talks to potentially buy NuVasive.

TSLA

Tesla

$305.75

-2.03 (-0.66%)

CAR

Avis Budget

$25.66

-0.45 (-1.72%)

NUVA

NuVasive

$49.55

-0.96 (-1.90%)

SNN

Smith & Nephew

$40.17

-0.12 (-0.30%)

QSR

Restaurant Brands

$62.71

0.425 (0.68%)

AVYA

Avaya

$17.72

0.07 (0.40%)

NVDA

Nvidia

$148.23

0.84 (0.57%)

CVLT

Commvault

$68.34

0.59 (0.87%)

BBBY

Bed Bath & Beyond

$15.41

0.07 (0.46%)

  • 11

    Feb

  • 11

    Feb

  • 14

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 06

    Mar

  • 14

    Mar

  • 18

    Mar

  • 20

    Mar

  • 21

    Mar

TSLA Tesla
$305.75

-2.03 (-0.66%)

02/05/19
UBSW
02/05/19
NO CHANGE
Target $465
UBSW
Buy
Tesla acquisition of dry electrode technology a positive, says UBS
UBS analyst Ben Kallo views Tesla's (TSLA) acquisition of Maxwell (MXWL) as positive and said its dry electrode technology may have been the key acquisition driver. The analyst said its technology could further enable cost reductions in the lithium-ion battery manufacturing process. Kallo reiterated his Buy rating and $465 price target on Tesla shares.
02/05/19
MSCO
02/05/19
NO CHANGE
Target $283
MSCO
Equal Weight
Morgan Stanley says Tesla managing expectations well, but stock fully valued
Morgan Stanley analyst Adam Jonas said Tesla has "very effectively managed expectations for 1Q19 and the full year," but he also believes the stock remains fully valued. Following the company's recent quarterly report, Jonas cut his 2019 unit volume forecast by 8% to 380,000 vehicles, which drove down his 2019 revenue view to $28B from $30B and led him to lower his price target on Tesla shares to $283 from $291. Jonas, who does not believe investors will assume the company is fully self-sufficient from a funding standpoint without a more sustained period of execution despite its recently strong results, keeps an Equal Weight rating on Tesla shares.
02/11/19
ADAM
02/11/19
UPGRADE
Target $450
ADAM
Buy
Canaccord upgrades Tesla to Buy with Model 3, governance concerns eased
As previously reported, Canaccord upgraded Tesla to Buy from Hold with analyst Jed Dorsheimer stating that he thinks electric vehicle, or EV, penetration is underappreciated by Wall Street. He believes the last two quarters and recent guidance have removed significant concerns for both production capability and profitability of the Model 3. Also, his prior corporate governance concerns were allayed with the addition of Larry Ellison and Ms. Wilson-Thompson as independent directors, Dorsheimer tells investors. Additionally, he sees Tesla as having "an almost insurmountable lead in autonomous driving," the analyst added in his upgrade note. He raised his price target on Tesla shares to $450 from $330.
02/11/19
ADAM
02/11/19
UPGRADE
ADAM
Buy
Tesla upgraded to Buy from Hold at Canaccord
CAR Avis Budget
$25.66

-0.45 (-1.72%)

10/16/18
10/16/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. NEEDHAM SAYS BUY TAPESTRY: Needham analyst Rick Patel upgraded Tapestry to Buy from Hold and kept his $50 price target. The analyst notes that after a 14% selloff in the stock price driven by tariff-related concerns and the slowdown of Asia sales at LVMH, the risk-reward is favorable. Patel estimates that the hit to EPS from the impact of the handbag tariff should be "relatively modest" at about 1%. The analyst further notes that Tapestry has "ample white space" for long term growth in China through new distribution, while its North America sales indicate "well-controlled promotions" for Coach and Kate Spade. ANALYSTS SAY BUY FACEBOOK IN NEW INITIATIONS: Loop Capital analyst Alan Gould initiated Facebook with a Buy rating and a price target of $210, saying the stock is valued "quite attractively" after a "strong year financially and a challenging year operationally". The analyst also notes that the company's guidance is likely "conservative" given the company's propensity to beat consensus estimates. Meanwhile, Rosenblatt analyst Mark Zgutowicz started Facebook with a Buy rating in a note partially entitled "Facebook: Value, Not Trap." Given the stock's current valuation, there appears to be little confidence consensus expectations will be met and he is "in that camp," forecasting calendar 2019 EPS that is about 8% below consensus, Zgutowicz tells investors. However, with that said, he sees the anticipated EPS shortfall as priced in the shares and would be a buyer of the stock in front of the Q3 report, stating that he sees a bottoming for News Feed fatigue and enough light ahead with new product innovation and Instagram and Watch optionality. Zgutowicz set a $213 price target on Facebook shares. TILRAY TARGET SET AT $200 AS CANADA GETS READY TO LEGALIZE: Benchmark analyst Mike Hickey initiated coverage of Tilray with a Buy rating and $200 price target, citing its early leadership in the medical cannabis market in Canada and the upcoming legalization of recreational cannabis, which begins in the North American nation tomorrow. He believes the company's strategic alliance with Novartis (NVS) and supply agreements with Canadian pharmacies that give Tilray a competitive edge in the Canadian medical cannabis market, Hickey tells investors. He also believes the potential international opportunity is "enormous," estimating that the global cannabis market opportunity could exceed $200B over the long-term. JEFFERIES SEES NO COMPETING BIDS FOR PINNACLE: Jefferies analyst Akshay Jagdale downgraded Pinnacle Foods (PF) to Hold from Buy and lowered his price target for the shares to $68 from $72. The analyst assumes Conagra Brands' (CAG) bid to buy the company for $68 will go through without any competing bids. The stock should trade in line with its $68 transaction price until completion of the deal, Jagdale tells investors. GOLDMAN PREDICTS AVIS, HERTZ OUTLOOKS WILL DISAPPOINT: Goldman Sachs analyst David Tamberrino nudged the price target on Avis Budget (CAR) lower to $30 from $31 while keeping the price target on Hertz at $13 as part of his broader research note previewing Q3 results for the two Sell-rated U.S. car rental names. The analyst notes that Hertz (HTZ) may top Q3 consensus earnings and Avis Budget could miss based on his analysis of their respective pricing trends and residual values, but both have an added risk from reduced airport volume growth amid tightening competition among the ride hailing operators like Uber and Lyft. Tamberrino expects the car rental industry to remain challenged overall, noting that positive pricing will not be sustained, residual values will be pressured as more cars come off lease, and rising interest rates exert pressure on their balance sheets' high debt levels.
12/06/18
LSCM
12/06/18
NO CHANGE
LSCM
I.D. Systems expansion with Avis provides multiple benefits, says Lake Street
Lake Street analyst Jaeson Schmidt reiterated a Buy rating and $9.50 price target on I.D. Systems (IDSY) after the company expanded its relationship with Avis (CAR) with a new 75K unit order. Schmidt believes the expansion has three key benefits for I.D. Systems -- It should be additive to the P&L as he estimates its value at over $30M, it was not a one-off order and he would not be surprised if the relationship was further expanded, and concerns on tough year-over-year comparisons should lessen.
10/16/18
GSCO
10/16/18
NO CHANGE
Target $30
GSCO
Sell
Goldman Sachs expects FY18 outlook for Avis Budget and Hertz to disappoint
Goldman Sachs analyst David Tamberrino nudged the price target on Avis Budget (CAR) lower to $30 from $31 while keeping the price target on Hertz at $13 as part of his broader research note previewing Q3 results for the two Sell-rated U.S. Car Rental names. The analyst notes that Hertz (HTZ) may top Q3 consensus earnings and Avis Budget could miss based on his analysis of their respective pricing trends and residual values, but both have an added risk from reduced airport volume growth amid tightening competition among the ride hailing operators like Uber and Lyft. Tamberrino expects the car rental industry to remain challenged overall, noting that positive pricing will not be sustained, residual values will be pressured as more cars come off lease, and rising interest rates exert pressure on their balance sheets' high debt levels.
02/11/19
GSCO
02/11/19
UPGRADE
Target $35
GSCO
Buy
Avis Budget upgraded to Buy from Sell at Goldman Sachs
Goldman Sachs analyst David Tamberrino double upgraded Avis Budget (CAR) to Buy from Sell and raised his price target for the shares to $35 from $30. The analyst also maintains a Sell rating on Hertz (HTZ). Trading at 6.2 times estimated 2019 EBITDA versus a historical trough multiple of 5.9 times and long-term average 8.4 times, shares of Avis look attractive for mean reversion, Tamberrino tells investors in a research note. The analyst believes most of the headwinds the industry is facing appear priced in at current share levels. Further, he views Avis as better positioned than Hertz and thinks it should be able to improve results through cost optimization strategies in 2019 and beyond.
NUVA NuVasive
$49.55

-0.96 (-1.90%)

02/11/19
CANT
02/11/19
NO CHANGE
Target $50
CANT
Neutral
Smith & Nephew unlikely to acquire NuVasive, says Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou thinks a Smith & Nephew (SNN) acquisition of NuVasive (NUVA) is unlikely as he sees more attractive acquisition targets that would better align with the company's goals. Specifically, there are better potential acquisition targets in end markets adjacent to Smith & Nephew with faster growth that would better leverage the company's existing businesses, Bijou tells investors in a research note. He points out the overall spine market is growing by only 0%-2%, below the market growth of Smith & Nephew's current end markets. However, the analyst expects the Financial Times' report on Friday of deal talks to put pressure on shares of Wright Medical (WMGI). Many investors believe that Smith & Nephew is a potential acquirer of Wright and a NuVasive deal would make that combo unlikely in the near term, Bijou contends. He keeps a Neutral rating on NuVasive with a $50 price target.
02/10/19
PIPR
02/10/19
NO CHANGE
Target $70
PIPR
Overweight
Piper Jaffray does not believe Smith & Nephew, NuVasive deal will occur
Following an article by the Financial Times that indicated Smith & Nephew (SNN) was in talks to acquire NuVasive (NUVA), Piper Jaffray analyst Matt O'Brien says he does not believe this transaction will occur as the spine market does not grow much making it less attractive than other orthopedic segments and the landscape is littered with failed spine deals. The analyst thinks investors in NuVasive should take some profit, and anticipates shares of Wright Medical (WMGI) will trade lower on Monday as the most likely suitor for them would be off the table if a NuVasive deal occurred. Finally, the analyst believes a Smith & Nephew/NuVasive combination would be positive for Globus Medical (GMED) and SeaSpine (SPNE) as they would likely take share in the category. O'Brien reiterates an Overweight rating and $ 70 price target on NuVasive's shares.
02/11/19
JEFF
02/11/19
NO CHANGE
Target $68
JEFF
Buy
Smith & Nephew buying NuVasive 'makes some sense,' says Jefferies
A potential acquisition of NuVasive (NUVA) "makes some sense" for Smith & Nephew (SNN) as it adds the number three spine company and adds to growth, Jefferies analyst Raj Denhoy tells investors in a research note. The analyst's model shows accretion in year two with return on invested capital 10% in year five. However, the timing of the reported talks is "strange" given the recent management change at NuVasive, adds the analyst. Further, Denhoy believes questions on if spine and NuVasive are the best places for Smith & Nephew to invest will persist. The analyst keeps a Buy rating on NuVasive with a $68 price target.
SNN Smith & Nephew
$40.17

-0.12 (-0.30%)

QSR Restaurant Brands
$62.71

0.425 (0.68%)

02/06/19
COWN
02/06/19
NO CHANGE
Target $71
COWN
Outperform
Cowen views Domino's Pizza as top acquisition candidate for Restaurant Brands
Cowen analyst Andrew Charles views Domino's Pizza (DPZ) as a preeminent candidate for Restaurant Brands (QSR) to acquire.The analyst noted Restaurant Brands is open to buying a fourth brand and Domino's, with its international franchisees, provides opportunities to accelerate the company's existing brands' global expansion. He also believes the company can benefit from Domino's digital and delivery best practices. Charles lays out purchase price scenarios in the $350 to $375 per share range for Domino's shares and he reiterated his Outperform rating and $71 price target on Restaurant Brands shares.
01/24/19
01/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Procter & Gamble (PG) upgraded to Hold from Sell at Berenberg with analyst James Targett saying his analysis showed large brands trend to outperform, particularly in home care, hygiene and parts of personal care and packaged food. 2. Restaurant Brands (QSR) upgraded to Outperform from Market Perform at BMO Capital with analyst Peter Sklar citing the company's announced dividend increase, strong preliminary comparable sales for Q4, and the appointment of an industry "operator" as CEO. 3. Incyte (INCY) upgraded to Buy from Hold at Gabelli and to Outperform from Market Perform at William Blair. 4. Kimberly-Clark (KMB) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Dara Mohsenian saying while its initial FY19 EPS guidance of $6.50-6.70 was 2.5% below the prior consensus at the midpoint, he views it as "reasonable." 5. Southern Company (SO) upgraded to Neutral from Sell at Citi with analyst Praful Mehta saying he believes the company's Vogtle site is showing "good progress" following a visit. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/24/19
UBSW
01/24/19
NO CHANGE
Target $74
UBSW
Buy
Restaurant Brands valuation inexpensive relative to peers, says UBS
UBS analyst Dennis Geiger believes meaningful upside exists for Restaurant Brands, citing the potential for Tim Horton's comp trends to continue to improve and Burger King comps easing while momentum remains strong. Geiger, who said its investors day can act as a catalyst, reiterated his Buy rating and $74 price target on Restaurant Brands.
01/24/19
01/24/19
UPGRADE
Target $74

Outperform
Restaurant Brands upgraded to Outperform at BMO Capital on comps, dividend hike
As previously reported, BMO Capital analyst Peter Sklar upgraded Restaurant Brands to Outperform from Market Perform and raised his price target to $74 from $58. The analyst cites the company's announced dividend increase, strong preliminary comparable sales for Q4, and the appointment of an industry "operator" as CEO. Sklar also believes that naming Daniel Schwartz as executive chairman is a positive development, suggesting that Restaurant Brands' prior phase of cost cutting is complete.
AVYA Avaya
$17.72

0.07 (0.40%)

01/07/19
MSCO
01/07/19
INITIATION
Target $18.5
MSCO
Equal Weight
Avaya initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Meta Marshall initiated Avaya with an Equal Weight rating and $18.50 price target, arguing that the company has more work to do to assure they are the technology choice when their installed base looks to move towards the cloud. Avaya has the largest installed base in the industry and a growing bench of cloud products, but they have been out-executed by smaller cloud-first competitors by under utilizing a partnership ecosystem to amplify their marketing, Marshall tells investors.
12/17/18
GSCO
12/17/18
INITIATION
Target $20
GSCO
Neutral
Avaya initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Rod Hall started Avaya with a Neutral rating and $20 price target. The analyst sees a "better leverage story" following the company's reorganization but believes an improved revenue trajectory is dependent on its cloud migration execution. He prefers to wait on the sidelines pending greater revenue growth visibility.
01/25/19
LEHM
01/25/19
UPGRADE
Target $21
LEHM
Overweight
Barclays sees over 40% upside in Avaya shares, upgrades to Overweight
Barclays analyst Raimo Lenschow upgraded Avaya to Overweight from Equal Weight and raised his price target for the shares to $21 from $20. The analyst sees over 40% upside for the stock despite the company's status as a "legacy tech vendor." Since its return from bankruptcy in January 2018, Avaya has been largely ignored by equity investors and is trading at very low multiples, Lenschow tells investors in a research note. A return to legacy tech peer multiples alone could result in significant share price appreciation, says the analyst. He believes ongoing execution towards Avaya's fiscal 2019 revenue growth targets and better cash conversion will be positive catalysts.
01/25/19
LEHM
01/25/19
UPGRADE
Target $21
LEHM
Overweight
Avaya upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Raimo Lenschow upgraded Avaya Holdings to Overweight and raised his price target for the shares to $21 from $20.
NVDA Nvidia
$148.23

0.84 (0.57%)

02/11/19
BERN
02/11/19
DOWNGRADE
BERN
Market Perform
Nvidia downgraded to Market Perform from Outperform at Bernstein
02/11/19
02/11/19
DOWNGRADE
Target $175

Market Perform
Nvidia downgraded to Market Perform at Bernstein after guidance cut
As previously reported, Bernstein analyst Stacy Rasgon downgraded Nvidia to Market Perform from Outperform following the company's "somewhat chilly guidance cut," which appears much more fundamentally demand-driven, with the question of the "true" run-rate of the gaming business remaining up in the air for now. The analyst believes the shares are likely to remain hamstrung. Rasgon also lowered his price target on the shares to $175 from $250.
01/30/19
MZHO
01/30/19
NO CHANGE
Target $28
MZHO
Buy
Mizuho trims AMD target to $28, says guidance better than feared
AMD (AMD) last night reported an in-line December quarter and guided to a softer March quarter with $1.25B in sales, but better than feared with a stronger 41% gross margin, Mizuho analyst Vijay Rakesh tells investors in a research note. While "the cat was out of the bag" with the Nvidia (NVDA) pre-announcement, the AMD guidance "was much better than concerns with the stock down ~12% ahead of earnings," says Rakesh. He lowered his price target for the shares to $28 from $30 and reiterates a Buy rating on AMD.
02/11/19
MSCO
02/11/19
NO CHANGE
Target $33
MSCO
Equal Weight
Micron 'ahead of itself' in short term, says Morgan Stanley
Morgan Stanley analyst Joseph Moore said he expects demand for cloud, PCs and phones to improve seasonally through the year, but he contends that buying DRAM stocks "because cloud spending will come back" is highly likely to end in disappointment as he thinks DRAM is fundamentally oversupplied. Moore sees 2019 as a difficult year for DRAM even with a sharp demand recovery in spending and would rather buy Intel (INTC) or NVIDIA (NVDA) for a cloud recovery, he tells investors. He maintains an Equal Weight rating on Micron (MU) shares, but added that he thinks the stock is "ahead of itself in the short term."
CVLT Commvault
$68.34

0.59 (0.87%)

02/11/19
PIPR
02/11/19
DOWNGRADE
Target $66
PIPR
Neutral
Commvault downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Andrew Nowinski downgraded CommVault Systems (CVLT) to Neutral and lowered his price target for the shares to $66 from $71. The analyst believes the recent management changes are a positive for the company, but he views the current estimates and prior guidance as unachievable. The consensus estimate for fiscal 2020 calls for 11.5% growth in software license revenue, though the market is only growing 4.7%, Nowinski tells investors in a research note. With increasing competition from Veeam, Rubrik, Cohesity and Dell Technologies (DELL), this target will be difficult to exceed, particularly with Commvault cutting investments in Sales & Marketing, says Nowinski. Further, he sees "little opportunity" for Commvault to get acquired, as he believes Veeam, Rubrik and Cohesity are more likely candidates.
02/04/19
JEFF
02/04/19
NO CHANGE
JEFF
Buy
Jefferies wouldn't be surprised to see strategic bidder for Ultimate Software
After Ultimate Software (ULTI) announced it has agreed to be acquired by private equity firms led by Hellman & Friedman for $331.50 in cash, Jefferies analyst Samad Samana said he was "not surprised" by the acquisition but he also would not be surprised to see a strategic buyer make a bid. The deal price of $331.50 is "fair," but he thinks a strategic buyer could potentially justify a higher price based on potential revenue and cost synergies, Samana tells investors. He expects the deal to provide a boost to the other publicly traded payroll software vendors, particularly Paylocity (PCTY), added the analyst, who also identifies Commvault (CVLT), Mimecast (MIME), Nice Systems (NICE) and Verint (VRNT) as Software stocks that "appear attractive" as potential targets.
01/30/19
LSCM
01/30/19
NO CHANGE
Target $69
LSCM
Buy
Commvault price target raised to $69 from $66 at Lake Street
Lake Street analyst Eric Martinuzzi raised his price target for Commvault Systems to $69 citing an multiple expansion for an expected increase in the company's revenue growth rate in fiscal 2020. The analyst believes Commvault's growth in its large enterprise business "appears to have legs" and he reiterates a Buy rating on the shares.
01/30/19
JEFF
01/30/19
NO CHANGE
Target $83
JEFF
Buy
Commvault exceeded Q3 expectations across all metrics, says Jefferies
Jefferies analyst John DiFucci says Commvault Systems exceeded fiscal Q3 expectations across all metrics, maintained guidance for Q4 total revenues, and raised Software guidance. This sets the stage for Commvault to meet expectations for two quarters in a row, "which would be anomalous for the company," DiFucci tells investors in a post-earnings research note. The analyst raised his price target for the shares to $83 from $80 and finds the stock's valuation compelling at current levels. He keeps a Buy rating on Commvault.
BBBY Bed Bath & Beyond
$15.41

0.07 (0.46%)

01/25/19
LOOP
01/25/19
NO CHANGE
Target $13
LOOP
Hold
Bed Bath & Beyond new concept store underwhelming, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Hold rating and $13 price target on Bed Bath & Beyond, saying his recent visit to the company's new larger next-generation store in Chicago was underwhelming. The analyst continues to question the company's expansion of home furnishings assortment, saying the "treasure hunt merchandise" was also not impressive.
01/02/19
LOOP
01/02/19
NO CHANGE
Target $12
LOOP
Hold
Loop Capital says Bed Bath Beyond, Amazon price gap widens to historical levels
Loop Capital analyst Anthony Chukumba kept his Hold rating and $12 price target on Bed Bath & Beyond (BBBY), saying his periodic pricing study demonstrated that the gap between the company and Amazon.com (AMZN) has widened back to its "historical level". The analyst sees this as a likely negative for the former, but also notes that that discounting has been a challenge in maintaining its gross margins. Chukumba maintains his forecasts on Bed Bath results ahead of next week's earnings, adding that while its stock trades at a discount to historical average levels, the 6.5-times expected forward earnings multiple is "in line" with other "secularly challenged specialty hardlines retailers."
02/11/19
LOOP
02/11/19
DOWNGRADE
Target $12
LOOP
Sell
Bed Bath & Beyond downgraded to Sell from Hold at Loop Capital
Loop Capital analyst Anthony Chukumba downgraded Bed Bath & Beyond to Sell and lowered his price target for the shares to $12 from $13. The retailer closed Friday up 8c to $15.42. The recent rally in the shares as unwarranted as management's "much better-than-expected" fiscal 2019 financial guidance is "unrealistic," Chukumba tells investors in a research note. The analyst sees sales growth and profitability headwinds for Bed Bath and says management has a "poor track record" of meeting consensus expectations. Further, shareholders are unlikely to be "bailed out" by a leveraged buyout or activist investment, contends Chukumba.
11/08/18
SBSH
11/08/18
NO CHANGE
Target $13
SBSH
Sell
Bed Bath & Beyond activist probability low, 'screens well' for LBO, says Citi
Citi analyst Kate McShane reiterated a Sell rating on Bed Bath & Beyond shares, noting that the company has faced and continues to face significant challenges despite having enacted a number of changes in recent years. She views activist involvement or an LBO as a low probability given the number of challenges faced, but added that Bed Bath "has always screened well" as an LBO candidate. In a leveraged buyout scenario, the company could cut the dividend, shut down stores and create a smaller store format as a private company, McShane said.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

, XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

13:26
02/16/19
02/16
13:26
02/16/19
13:26
Periodicals
Amazon a risk for almost every stock/sector, Barron's says »

Amazon (AMZN) is eating…

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

XPO

XPO Logistics

$52.01

-7.535 (-12.65%)

KR

Kroger

$29.50

0.54 (1.86%)

FAST

Fastenal

$62.97

0.61 (0.98%)

GWW

Grainger

$316.63

4.9 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

YETI

Yeti

$22.85

0.97 (4.43%)

13:20
02/16/19
02/16
13:20
02/16/19
13:20
Periodicals
Yeti stock has 60% upside, Barron's says »

Yeti Holdings stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

L

Loews

$46.67

0.785 (1.71%)

13:14
02/16/19
02/16
13:14
02/16/19
13:14
Periodicals
Investors can love Loews, Barron's says »

Loews is a $15B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 28

    May

EQIX

Equinix

$421.53

1.16 (0.28%)

, COR

CoreSite Realty

$102.69

0.625 (0.61%)

13:10
02/16/19
02/16
13:10
02/16/19
13:10
Periodicals
Equinix, CoreSite Realty among stocks to play data-center boom, Barron's says »

Data-center stocks may…

EQIX

Equinix

$421.53

1.16 (0.28%)

COR

CoreSite Realty

$102.69

0.625 (0.61%)

IRM

Iron Mountain

$35.13

-0.14 (-0.40%)

INXN

Interxion

$64.65

0.81 (1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 26

    Mar

  • 26

    Mar

NOK

Nokia

$6.31

0.015 (0.24%)

, ERIC

Ericsson

$9.36

0.015 (0.16%)

13:07
02/16/19
02/16
13:07
02/16/19
13:07
Periodicals
A U.S. ban of Huawei may benefit Ericsson, Samsung, Barron's says »

The next salvo in the…

NOK

Nokia

$6.31

0.015 (0.24%)

ERIC

Ericsson

$9.36

0.015 (0.16%)

SSNLF

Samsung

$0.00

(0.00%)

CSCO

Cisco

$49.45

1.05 (2.17%)

JNPR

Juniper

$27.12

0.16 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

COP

ConocoPhillips

$70.13

1.04 (1.51%)

, MUR

Murphy Oil

$29.23

0.59 (2.06%)

13:00
02/16/19
02/16
13:00
02/16/19
13:00
Periodicals
Dividend investors should look to oil stocks for big yields, Barron's says »

Energy stocks aren't…

COP

ConocoPhillips

$70.13

1.04 (1.51%)

MUR

Murphy Oil

$29.23

0.59 (2.06%)

CVX

Chevron

$119.30

1.19 (1.01%)

VLO

Valero

$84.34

0.75 (0.90%)

XOM

Exxon Mobil

$77.74

1.47 (1.93%)

MRO

Marathon Oil

$17.07

0.15 (0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 07

    Mar

  • 18

    Mar

  • 22

    May

  • 28

    May

AMZN

Amazon.com

$1,608.88

-13.47 (-0.83%)

12:45
02/16/19
02/16
12:45
02/16/19
12:45
Periodicals
Protestors against NY's Amazon HQ2 got math wrong, Barron's says »

On Thursday, Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 20

    Feb

  • 20

    Feb

  • 03

    Mar

  • 18

    Mar

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

, NDAQ

Nasdaq

$87.74

0.56 (0.64%)

12:28
02/16/19
02/16
12:28
02/16/19
12:28
Periodicals
Investors interested in U.S. cannabis companies face challenges, Barron's says »

Investors interested in…

ICE

IntercontinentalExchange

$75.49

-0.46 (-0.61%)

NDAQ

Nasdaq

$87.74

0.56 (0.64%)

CGC

Canopy Growth

$47.54

1.49 (3.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 28

    May

  • 15

    Feb

AMD

AMD

$23.68

0.55 (2.38%)

, INTC

Intel

$51.64

0.85 (1.67%)

08:43
02/16/19
02/16
08:43
02/16/19
08:43
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMD

AMD

$23.68

0.55 (2.38%)

INTC

Intel

$51.64

0.85 (1.67%)

MRVL

Marvell

$18.82

-0.37 (-1.93%)

MCHP

Microchip

$91.10

0.49 (0.54%)

MU

Micron

$41.99

-0.23 (-0.54%)

NVDA

Nvidia

$157.22

2.69 (1.74%)

QCOM

Qualcomm

$51.97

0.42 (0.81%)

TXN

Texas Instruments

$107.55

0.57 (0.53%)

TWTR

Twitter

$31.23

0.28 (0.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 07

    Mar

  • 07

    Mar

  • 25

    Mar

  • 26

    Mar

  • 28

    May

  • 04

    Jun

  • 05

    Jun

AMGN

Amgen

$188.31

1.6 (0.86%)

, ALPMY

Astellas Pharma

$0.00

(0.00%)

04:55
02/16/19
02/16
04:55
02/16/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2019 ASCO Genitourinary…

AMGN

Amgen

$188.31

1.6 (0.86%)

ALPMY

Astellas Pharma

$0.00

(0.00%)

AZN

AstraZeneca

$40.92

0.93 (2.33%)

BAYRY

Bayer

$0.00

(0.00%)

BMY

Bristol-Myers

$51.64

0.81 (1.59%)

CALA

Calithera Biosciences

$5.35

0.14 (2.69%)

CLVS

Clovis

$25.44

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

ESALY

Eisai

$0.00

(0.00%)

EXEL

Exelixis

$22.26

-0.05 (-0.22%)

IMMU

Immunomedics

$14.23

0.225 (1.61%)

INO

Inovio

$3.70

0.01 (0.27%)

MRK

Merck

$79.84

0.9 (1.14%)

MYOV

Myovant Sciences

$21.48

0.1 (0.47%)

MYGN

Myriad Genetics

$31.41

0.53 (1.72%)

NH

NantHealth

$0.60

(0.00%)

NVS

Novartis

$89.89

0.865 (0.97%)

PFE

Pfizer

$42.41

0.45 (1.07%)

PGNX

Progenics

$4.87

0.13 (2.74%)

SGEN

Seattle Genetics

$71.48

2.92 (4.26%)

SNY

Sanofi

$42.51

0.94 (2.26%)

TYME

Tyme Technologies

$3.19

0.055 (1.76%)

AVEO

Aveo Pharmaceuticals

$0.62

0.0092 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 16

    Feb

  • 19

    Feb

  • 20

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 11

    Mar

  • 22

    Mar

  • 11

    Apr

  • 28

    Apr

  • 18

    May

  • 20

    May

WES

Western Gas Partners

$49.52

0.38 (0.77%)

, WGP

Western Gas Equity

$32.38

0.2 (0.62%)

19:30
02/15/19
02/15
19:30
02/15/19
19:30
Recommendations
Western Gas Partners, Western Gas Equity analyst commentary at MUFG »

MUFG raises price targets…

WES

Western Gas Partners

$49.52

0.38 (0.77%)

WGP

Western Gas Equity

$32.38

0.2 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

  • 15

    Feb

  • 04

    Mar

PXD

Pioneer Natural

$145.33

2.27 (1.59%)

19:19
02/15/19
02/15
19:19
02/15/19
19:19
Recommendations
Pioneer Natural analyst commentary at MUFG »

Pioneer Natural price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

ZTS

Zoetis

$95.38

2.16 (2.32%)

18:42
02/15/19
02/15
18:42
02/15/19
18:42
Hot Stocks
Zoetis CEO says: 'Diagnostics are more important in animals than humans' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$136.40

2.13 (1.59%)

18:22
02/15/19
02/15
18:22
02/15/19
18:22
Hot Stocks
Johnson & Johnson CEO: 'We ended 2018 with great results' »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 25

    Feb

  • 25

    Feb

  • 06

    Mar

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

18:18
02/15/19
02/15
18:18
02/15/19
18:18
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

BHVN

Biohaven Pharmaceutical

$45.32

1.36 (3.09%)

18:14
02/15/19
02/15
18:14
02/15/19
18:14
Hot Stocks
Biohaven treatment of multiple system atrophy granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$188.31

1.6 (0.86%)

18:11
02/15/19
02/15
18:11
02/15/19
18:11
Hot Stocks
Amgen treatment of Acute Myeloid Leukemia granted FDA orphan designation »

According to a post on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$100.19

1.19 (1.20%)

18:02
02/15/19
02/15
18:02
02/15/19
18:02
Hot Stocks
Celanese announces Acetyl Intermediates price increases in China »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$3.37

0.2 (6.31%)

, UNIT

Uniti Group

$20.00

0.53 (2.72%)

17:58
02/15/19
02/15
17:58
02/15/19
17:58
Periodicals
Court says Windstream defaulted on bonds in 2015, Bloomberg says »

A court has ruled that…

WIN

Windstream

$3.37

0.2 (6.31%)

UNIT

Uniti Group

$20.00

0.53 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 28

    Feb

GLD

SPDR Gold Shares

$124.81

0.77 (0.62%)

17:41
02/15/19
02/15
17:41
02/15/19
17:41
Hot Stocks
SPDR Gold Shares holdings fall to 793.03MT from 796.85MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDLZ

Mondelez

$48.17

0.84 (1.77%)

17:26
02/15/19
02/15
17:26
02/15/19
17:26
Hot Stocks
Mondelez to transfer listing of debt securities to Nasdaq »

Mondelez International,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Feb

  • 06

    Mar

  • 28

    May

FN

Fabrinet

$55.23

0.67 (1.23%)

17:25
02/15/19
02/15
17:25
02/15/19
17:25
Hot Stocks
Fabrinet CFO sells 20K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 04

    Mar

UBER

Uber

$0.00

(0.00%)

17:24
02/15/19
02/15
17:24
02/15/19
17:24
Periodicals
Uber sues NYC over move to cap number of ride-hailing drivers, Bloomberg says »

Uber is suing New York…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

17:19
02/15/19
02/15
17:19
02/15/19
17:19
Periodicals
House Democrats to probe POTUS emergency declaration, Bloomberg says »

The House Judiciary…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.40

2.93 (1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$51.71

0.25 (0.49%)

17:11
02/15/19
02/15
17:11
02/15/19
17:11
Hot Stocks
Oracle authorizes additional $12B stock buyback under existing program »

In a regulatory 8K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

  • 06

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.